ATE403736T1 - Onkolytische adenovirale vektoren - Google Patents

Onkolytische adenovirale vektoren

Info

Publication number
ATE403736T1
ATE403736T1 AT02714960T AT02714960T ATE403736T1 AT E403736 T1 ATE403736 T1 AT E403736T1 AT 02714960 T AT02714960 T AT 02714960T AT 02714960 T AT02714960 T AT 02714960T AT E403736 T1 ATE403736 T1 AT E403736T1
Authority
AT
Austria
Prior art keywords
adenoviral vectors
adenoviral
nucleic acid
viral vector
oncolytic adenoviral
Prior art date
Application number
AT02714960T
Other languages
English (en)
Inventor
David Ennist
Suzanne Forry-Schaudies
Mario Gorziglia
Paul Hallen-Beck
Carl Hay
John Jakubczak
Michael Kaleko
Patricia Ryan
David Stewart
Yuefeng Xie
Sheila Connelly
Seshidhar Reddy Police
Lori Clarke
Sandrina Phipps
Cheng Cheng
Original Assignee
Cell Genesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Genesys Inc filed Critical Cell Genesys Inc
Application granted granted Critical
Publication of ATE403736T1 publication Critical patent/ATE403736T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/007—Vector systems having a special element relevant for transcription cell cycle specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT02714960T 2001-02-23 2002-02-22 Onkolytische adenovirale vektoren ATE403736T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27092201P 2001-02-23 2001-02-23
US29503701P 2001-06-01 2001-06-01
US34867002P 2002-01-14 2002-01-14

Publications (1)

Publication Number Publication Date
ATE403736T1 true ATE403736T1 (de) 2008-08-15

Family

ID=27402327

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02714960T ATE403736T1 (de) 2001-02-23 2002-02-22 Onkolytische adenovirale vektoren

Country Status (8)

Country Link
US (1) US20030104625A1 (de)
EP (1) EP1377671B1 (de)
JP (1) JP2004529627A (de)
AT (1) ATE403736T1 (de)
CA (1) CA2439115A1 (de)
DE (1) DE60228066D1 (de)
IL (1) IL152420A0 (de)
WO (1) WO2002067861A2 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998205A (en) * 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6492343B1 (en) * 1998-04-15 2002-12-10 University Of Saskatchewan Porcine adenovirus type 3 genome
US6900049B2 (en) * 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US7569217B2 (en) * 2001-09-24 2009-08-04 University Of Saskatchewan Porcine adenovirus E1 and E4 regions
US20030143200A1 (en) * 2001-09-24 2003-07-31 Tikoo Suresh K. Porcine adenovirus E1 region
EP1496979A4 (de) * 2002-03-22 2007-10-31 Univ Texas Protamin-adenovirale vektor-komplexe und anwendungsverfahren
US8163892B2 (en) * 2002-07-08 2012-04-24 Oncolys Biopharma, Inc. Oncolytic virus replicating selectively in tumor cells
JP3867968B2 (ja) * 2002-07-08 2007-01-17 関西ティー・エル・オー株式会社 腫瘍細胞において選択的に増殖する腫瘍融解ウイルス
US7364727B2 (en) 2002-07-22 2008-04-29 Cell Genesys, Inc. Metastatic colon cancer specific promoter and uses thereof
AU2003287451A1 (en) 2002-11-01 2004-06-07 Cell Genesys, Inc. Cell-specific adenovirus vector comprising ebv-specific promoter
US20070099177A1 (en) * 2002-11-14 2007-05-03 Heim Albert R Agents and methods for detecting human adenoviruses
US20070275915A1 (en) * 2003-04-15 2007-11-29 Cell Genesys, Inc. Tmprss2 Regulatory Sequences and Uses Thereof
WO2005017149A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
AU2003265873A1 (en) * 2003-08-28 2005-04-14 Cell Genesys, Inc. Oncolytic adenoviral vectors encoding gm-csf
US20050186178A1 (en) * 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
US7482156B2 (en) * 2003-10-15 2009-01-27 Cell Genesys, Inc. Hepatocellular carcinoma specific promoter and uses thereof
US20050097066A1 (en) * 2003-10-31 2005-05-05 Pitney Bowes Incorporated Method and system for a mailing machine to verify the integrity of printed postage
US20070207461A1 (en) 2004-02-23 2007-09-06 Crucell Holland B.V. Virus Purification Methods
US7473418B2 (en) * 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
PT2484365E (pt) * 2004-06-04 2013-12-12 Scripps Research Inst Composições e métodos para o tratamento de doenças neovasculares
CN100361710C (zh) * 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
US20060062764A1 (en) * 2004-08-25 2006-03-23 Seshidar-Reddy Police Fiber-modified adenoviral vectors for enhanced transduction of tumor cells
CA2602944C (en) 2005-04-11 2015-08-11 Crucell Holland B.V. Virus purification using ultrafiltration
KR100756055B1 (ko) * 2006-01-27 2007-09-07 연세대학교 산학협력단 신생혈관 생성을 조절하는 재조합 아데노바이러스
CN100488568C (zh) * 2006-04-03 2009-05-20 南京师范大学 一种能分泌内皮抑素的细胞制剂及其在制备治疗肿瘤的药中的应用
WO2008108890A2 (en) * 2006-10-18 2008-09-12 University Of Rochester Conditionally replicating viruses for cancer therapy
EP1947463A1 (de) * 2007-01-16 2008-07-23 Roche Diagnostics GmbH Entnahme von flüssigen Analyseproben zum Zweck der klinischen Analyse
US9707285B2 (en) 2009-03-16 2017-07-18 Turnstone Limited Partnership Vaccination methods
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
EP2896632B1 (de) 2009-11-13 2017-10-25 Daiichi Sankyo Europe GmbH Material und Verfahren zur Behandlung oder Vorbeugung von HER-3-assoziierten Erkrankungen
WO2012000188A1 (en) * 2010-06-30 2012-01-05 Tot Shanghai Rd Center Co., Ltd. Recombinant tumor vaccine and method of producing such
WO2012018404A2 (en) 2010-08-06 2012-02-09 U3 Pharma Gmbh Use of her3 binding agents in prostate treatment
FI123955B (en) 2011-11-25 2014-01-15 Oncos Therapeutics Ltd Oncolytic adenovirus
JP6188728B2 (ja) 2012-02-07 2017-08-30 グローバル・バイオ・セラピューティクス・インコーポレイテッドＧｌｏｂａｌ Ｂｉｏ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 核酸送達の区画化方法ならびにその組成物および使用
US20140350087A9 (en) 2012-03-22 2014-11-27 Halozyme, Inc. Oncovector Nucleic Acid Molecules and Methods of Use
JP2016513115A (ja) 2013-02-21 2016-05-12 チルドレンズ ホスピタル オブ イースタン オンタリオ リサーチ インスティチュート インコーポレイテッド ワクチン組成物
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
CN103555765B (zh) * 2013-05-30 2015-01-07 中南大学湘雅医院 一种转录调控肿瘤靶向复制溶瘤腺病毒载体、携带治疗基因腺病毒及其制备方法和应用
HK1225258B (en) 2013-08-08 2017-09-08 Global Bio Therapeutics, Inc. Clamping device for minimally invasive surgery
KR102608590B1 (ko) 2014-09-24 2023-12-01 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양 살상 바이러스 및 이의 사용방법
EP3329934B1 (de) * 2015-09-01 2021-03-24 Genemedicine Co., Ltd. Zusammensetzung zur erhöhung der antitumorimmunität mit adenovirus zur gleichzeitigen expression von il-12 und shvegf
CN109104870B (zh) * 2016-01-15 2021-10-15 丁恩雨 一种能够增强mRNA稳定性和可译性的通用核酸药物载体
WO2017147269A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
EP3532082A4 (de) 2016-12-12 2020-08-26 Salk Institute for Biological Studies Auf tumoren gerichtete synthetische adenoviren und verwendungen davon
JP6956800B2 (ja) * 2017-03-25 2021-11-02 ジェン−プローブ・インコーポレーテッド アデノウイルス、メタニューモウイルス、および／またはライノウイルス核酸を検出するための組成物、方法、およびキット
JP7216668B2 (ja) 2017-05-26 2023-02-01 エピセントアールエックス，インコーポレイテッド 導入遺伝子を保持する組換えアデノウイルス
EP3681998A1 (de) 2017-09-11 2020-07-22 IMBA-Institut für Molekulare Biotechnologie GmbH Tumororganoidmodell
CN111542601A (zh) * 2017-11-08 2020-08-14 国立大学法人鹿儿岛大学 确保安全并且能够有效地治疗甚至转移性癌症的、具有提供装载的免疫诱导基因的最佳表达水平的表达控制系统的肿瘤溶解性病毒(肿瘤溶解性免疫治疗)
US11857585B2 (en) * 2017-12-28 2024-01-02 Bionoxx Inc. Oncolytic virus improved in safety and anticancer effect
CN112292449A (zh) 2018-04-09 2021-01-29 萨克生物研究学院 具有增强的复制特性的溶瘤腺病毒组合物
JP7316711B2 (ja) 2019-08-19 2023-07-28 ナンジン・ノベル・バイオテクノロジー・カンパニー・リミテッド 脂質代謝を調節する複製腫瘍溶解性アデノウイルス及びその応用
US20240366681A1 (en) 2021-08-13 2024-11-07 Triovance Holding Llc A skin substitute composition and methods of producing and using the same
CN117568405B (zh) * 2023-11-14 2024-06-14 武汉凯德维斯生物技术有限公司 一种溶瘤腺病毒重组载体、构建方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998205A (en) * 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US5880102A (en) * 1995-01-17 1999-03-09 Duke University Adenoviral vector system
FR2763958A1 (fr) * 1997-05-29 1998-12-04 Transgene Sa Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique
WO2000018903A2 (en) * 1998-09-29 2000-04-06 The Johns Hopkins University Inducible genetic suppression of cellular excitability
WO2000031286A1 (en) * 1998-11-20 2000-06-02 Valentis, Inc. Adenoviral vector-mediated delivery of modified steroid hormone receptors and related products and methods
US6420345B1 (en) * 1999-03-01 2002-07-16 Cell Genesys, Inc. Methods and reagents for inhibiting angiogenesis
US7396679B2 (en) * 1999-11-15 2008-07-08 Onyx Pharmaceuticals, Inc. Oncolytic adenovirus

Also Published As

Publication number Publication date
JP2004529627A (ja) 2004-09-30
WO2002067861A2 (en) 2002-09-06
CA2439115A1 (en) 2002-09-06
DE60228066D1 (de) 2008-09-18
EP1377671B1 (de) 2008-08-06
EP1377671A2 (de) 2004-01-07
IL152420A0 (en) 2003-05-29
US20030104625A1 (en) 2003-06-05
WO2002067861A3 (en) 2003-08-21

Similar Documents

Publication Publication Date Title
DE60228066D1 (de) Onkolytische adenovirale vektoren
Ward et al. Stringent chemical and thermal regulation of recombinant gene expression by vaccinia virus vectors in mammalian cells.
US10316065B2 (en) Oncolytic adenoviruses for treating cancer
EP0753068B1 (de) Adenovirusfaser mit hinzugefügten liganden
US6294377B1 (en) Adenoviral vectors of canine origin
ATE332965T1 (de) Komplementierende zellinien
JP2020010684A5 (de)
CA2229631A1 (en) Gene therapy using ovine adenoviral vectors
ATE470704T1 (de) Rekombinantes sendai-virus
WO2005005610A3 (en) Mutant adeno-associated virus virions and methods of use thereof
IS4754A (is) Genaferjur og aðferðir fyrir genaflutning inn í frumur
WO2001027304A3 (en) Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna
WO2000073478A3 (en) Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
US20030175244A1 (en) Capsid-modified recombinant adenovirus and methods of use
KR100469936B1 (ko) 사스 바이러스 항원의 세포표면 발현벡터 및 상기 벡터에의해 형질전환된 미생물
Pearce et al. Glycoviruses: chemical glycosylation retargets adenoviral gene transfer
EP1015009A4 (de) abgeschwächte VIF DNA Immunisierungscassetten als genetische Impfstoffe
BR9609102A (pt) Construção de dna recombinante e vetor útil para produzir transformantes de células de hospedeiro bacteriano
WO2003029433A3 (en) Chimeric viral vectors for gene therapy
CA2294649A1 (en) Bovine adenovirus type 3 genome
WO2001044458A3 (en) Bovine immunodeficiency virus (biv) based vectors
Cai et al. Organization of the avian adenovirus genome and the structure of its endopeptidase
WO2004087886A3 (en) Modified adenoviral e1a constructs and methods of use thereof
WO2002008436A3 (en) Mini-adenoviral vector system for vaccination
Knopf et al. The DNA replication origins of herpes simplex virus type 1 strain Angelotti

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties